BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
TGFB1
,
Angiogenesis
,
Pseudomonas infection
,
Neuron
,
Autoimmunity
,
Quercetin
,
rs2230926
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
c 15
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
L1000 CMAP - Embryonic kidney epithelial HA1E cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Non-small cell lung cancer HCC515 cells treated with ligand perturbagens
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
A novel allele, HLA-C*15:227, identified when typing COVID-19 patients.
Identification of a novel HLA-C*15 allele, HLA-C*15:96Q.
Identification of a novel HLA-C*15 allele, HLA-C*15:02:21.
Identification of the novel allele, HLA-C*15:02:01:03, by full-length genomic sequencing.
Re-evaluation of the Fijianolide/Laulimalide Chemotype Suggests an Alternate Mechanism of Action for…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Re…
Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active …
Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefract…
Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients
Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When …
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ